Tim Forshew

TL;DR: This proof-of-concept analysis showed that circulating tumor DNA is an informative, inherently specific, and highly sensitive biomarker of metastatic breast cancer.

TL;DR: Serial analysis of cancer genomes in plasma constitutes a new paradigm for the study of clonal evolution in human cancers, establishing proof of principle that exome-wide analysis of circulating tumour DNA could complement current invasive biopsy approaches to identify mutations associated with acquired drug resistance in advanced cancers.

TL;DR: Levels of mutant alleles reflected the clinical course of the disease and its treatment—for example, stabilized disease was associated with low allelic frequency, whereas patients at relapse exhibited a rise in frequency, and TAm-Seq will need to achieve a more sensitive detection limit to identify mutations in the plasma of patients with less advanced cancers.

TL;DR: It is reported that mutp53 prolongs TNF-α-induced NF-κB activation in cultured cells and intestinal organoid cultures, and might explain the early appearance of p53 mutations in human CAC.

TL;DR: It is shown that mutp53 regulates the tumor microenvironment by inducing the release of specific exosomes containing miR-1246 that once received by macrophage turns them into tumor supportive macrophages, which strongly support a microenvironmental GOF role for mut p53 in actively engaging the immune system to promote cancer progression and metastasis.